+8%

est. 2Y upside i

HealthcareSeries D+

Type 2 diabetes reversal and metabolic health platform

Rank

#2957

Sector

HealthTech

Est. Liquidity

~2Y

Data Quality

Data: Medium

Virta Health presents a moderate upside opportunity for a job seeker.

Last updated: March 10, 2026

Bull (35%)+75%

Continued strong revenue growth (80%+ YoY) and successful integration of GLP-1 management, expanding market share in both diabetes and obesity, leading to a successful IPO at a premium valuation of $3.5B (1.75x current valuation) by 2027.

Base (40%)+25%

Sustained strong revenue growth (e.g., 50-60% YoY) and continued profitability, leading to an IPO or acquisition at a valuation of $2.5B (1.25x current valuation) within 2 years, reflecting solid execution in a competitive market.

Bear (25%)-35%

Increased competition and pricing pressure, particularly from GLP-1 focused solutions, or a delayed/unfavorable IPO market, resulting in a flat or down round/exit at $1.3B (-35% from current valuation), significantly impacting common stock value due to liquidation preferences.

Est. time to liquidity~1.5 years
Adjusted for competitive dynamics: 23% (raw: 8%, adjustment: -5%)

Preference Stack Risk

high

Funding Intensity

23%

Investors hold $465M in liquidation preferences ahead of common stock. In an exit at or below $2.0B, common shareholders would receive value only after these preferences are paid out.

Dilution Risk

moderate

As a Series E company aiming for an IPO, significant further private funding rounds are less likely, but an IPO itself will involve some dilution for existing shareholders.

Secondary Liquidity

limited

While platforms exist for accredited investors, market activity for Virta Health stock is described as low with few buyers or sellers.

Product Development — 5 roles

Finance & Legal — 1 role

People & Places — 1 role

View all 21 open roles at Virta Health →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Virta Health's data — designed to show you've done your homework.

  • 1

    “How is Virta Health strategically positioning its nutrition-first approach alongside the increasing prevalence and insurer requirements for GLP-1 prescriptions, particularly against competitors like Omada Health who are also expanding into obesity care?”

  • 2

    “Given the stated goal of being IPO-ready in 2026 and the current $160M ARR with 80% YoY growth, what are the key milestones and financial targets the company needs to hit to ensure a successful public offering?”

  • 3

    “With $465M in total funding and a $2.0B valuation, how does the company plan to manage potential dilution for employees during a future liquidity event, and what are the expectations for secondary liquidity options for common shareholders in the interim?”

Cluster Peers

Expected Upside

Omada Health
+39%
Noom
-18%

Community

Valuation Sentiment

Our model estimates +8% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.